BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Space station changes command, setting stage for Crew 11 departure- From ‘Project Hail Mary’ to Artemis II, spaceflight captures audiences when it centers on people because human space travel is hazardous
- A Manual for Pick Dependable Vehicle Rental Administrations For 2024
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- The most effective method to Pick a Campervan That Offers Something else for Less
- Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
